Skip to main content
. 2021 Mar 12;15(3):e0009231. doi: 10.1371/journal.pntd.0009231

Fig 1. In vivo protective activity of anti-IpaD/SipD antibodies against S. flexneri 2a and S. Typhimurium challenges.

Fig 1

Mice (N = 10) were injected with a total of 300 μg/mouse of the indicated anti-IpaD/SipD antibodies (alone or in combination) 24 h before (A, B) the intragastric (S. Typhimurium, A, C) or intranasal (S. flexneri 2a, B, D) 100 LD50 challenge and at the onset of the signs (C, D). Survival was monitored for 30 days. Statistical analysis was performed using a log-rank (Mantel-Cox) test comparing mice treated with mAbs versus control mice treated by a control non-relevant IgG1 antibody.